Macro Finance
Dermatology Biotech Bambusa Dips 6.3% After $168.9 Million IPO
Bloomberg Markets·October 30, 2026·1 min read
Bambusa Therapeutics Inc. shares fell 6.3% in its trading debut after the early-stage biotech focused on dermatology and autoimmune diseases raised $168.9 million in a US initial public offering. The stock's decline reflects investor caution toward newly listed biotech firms amid a volatile market for healthcare IPOs.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.